GBA1–PD patients exhibit deregulation of the presynaptic dopamine terminal function observed as significant dopamine transporter (DAT) deficit, mainly in the striatum contralateral to the more affected side [42]. This evidence concerns the gene SLC6A3 and Parkinson disease.